3350.F AADI BIOSCIENCES DL-0001
- Market cap
- EUR 159M
- P/E
- -
- P/B
- 1.10x
- ROE
- -49.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 3350.F undervalued?
Graham numberThe Graham number of AADI BIOSCIENCES DL-0001 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
AADI BIOSCIENCES DL-0001 fundamental analysis
No fundamental analysis for AADI BIOSCIENCES DL-0001 yet.
AADI BIOSCIENCES DL-0001 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About AADI BIOSCIENCES DL-0001
Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in August 2021. Whitehawk Therapeutics, Inc. was incorporated in 2007 and is headquartered in Morristown, New Jersey.
Full company profileAADI BIOSCIENCES DL-0001 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
AADI BIOSCIENCES DL-0001 annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 1.00M | 15.2M | 24.4M | 26.0M | 7.15M | 0.00 |
| Gross Profit | 1.00M | 13.9M | 21.5M | 23.0M | 6.39M | 0.00 |
| Operating Income | -37.1M | -59.0M | -71.9M | -64.8M | -114M | -86.1M |
| EBITDA | - | -60.1M | -65.4M | -63.3M | -20.5M | -86.1M |
| Net Income | -110M | -60.5M | -65.8M | -63.7M | -20.6M | -80.1M |
| EPS | -5.27 | -2.48 | -2.68 | -2.58 | -0.44 | -1.36 |
| Balance Sheet | ||||||
| Total Assets | 158M | 184M | 132M | 70.3M | 151M | 174M |
| Total Liabilities | 21.5M | 25.9M | 27.2M | 17.8M | 14.5M | 10.5M |
| Shareholders' Equity | 136M | 158M | 105M | 52.5M | 136M | 163M |
| Cash & Short-term Investments | 149M | 39.0M | 62.9M | 28.7M | 37.6M | 69.0M |
| Cash Flow | ||||||
| Operating Cash Flow | -22.4M | -49.6M | -59.7M | -59.6M | -97.4M | -75.2M |
| Capital Expenditure | 46.0K | 444K | 3.97M | 1.65M | 552K | 0.00 |
| Free Cash Flow | -22.5M | -50.1M | -63.6M | -61.2M | -98.0M | -75.2M |
| Ratios | ||||||
| ROE | -80.7% | -38.2% | -62.5% | -121.4% | -15.1% | -49.1% |
| ROA | -69.7% | -32.8% | -49.7% | -90.6% | -13.7% | -46.1% |
| Net Profit Margin | -11,009.0% | -397.7% | -270.0% | -245.1% | -288.3% | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
AADI BIOSCIENCES DL-0001 dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | USD 4.41M | 0.21 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns AADI BIOSCIENCES DL-0001
- Insiders 12.20%
- Institutions 79.90%
- Public & others 7.90%
- Shares outstanding 59.0M
- Free float 29.8M
AADI BIOSCIENCES DL-0001 company profile
- Company name
- AADI BIOSCIENCES DL-0001
- Ticker
- 3350.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 37
- Fiscal year end
- December
- Address
- 2 Headquarters Plaza, Morristown, NJ, United States, 07960
- Phone
- 551 321 2234
- Website
- ir.whitehawktx.com
About AADI BIOSCIENCES DL-0001
Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in August 2021. Whitehawk Therapeutics, Inc. was incorporated in 2007 and is headquartered in Morristown, New Jersey.
AADI BIOSCIENCES DL-0001 management
7- Dr. David J. Lennon Ph.D.President, CEO & Director · born 1971
- Dr. Neil P. Desai Ph.D.Founder & Director · born 1965
- Mr. Scott M. Giacobello CPACFO, Treasurer, Investor Relations & Corporate Communications · born 1970
- Mr. Bryan BallChief Technical Operations Officer · born 1970
- Dr. David Dornan Ph.D.Chief Scientific Officer · born 1978
- Mr. Stephen M. Rodin J.D.Senior VP of Legal & General Counsel · born 1976
- Dr. Margaret Han Dugan M.D.Chief Medical Officer · born 1957